Psoriasis Vulgaris: An Evidence-Based Guide for Primary Care

References

1. 1.↵
   1. Naldi L

   . Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121–8.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Levine D,
   2. Gottlieb A

   . Evaluation and management of psoriasis: an internist's guide. Med Clin North Am 2009;93:1291–303.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Patel RV,
   2. Lebwohl M

   . In the clinic. Psoriasis. Ann Intern Med 2011;155:ITC2-1-15; quiz ITC2–16.

   OpenUrl
4. 4.↵
   1. Ebell MH,
   2. Siwek J,
   3. Weiss BD,
   4. et al

   . Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17:59–67.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Tracey D,
   2. Klareskog L,
   3. Sasso EH,
   4. Salfeld JG,
   5. Tak PP

   . Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.
   1. de Andrade Lima E,
   2. de Andrade Lima M

   . Reviewing concepts in the immunopathogenesis of psoriasis [article in Portuguese]. An Bras Dermatol 2011;86:1151–8.

   OpenUrlPubMed
7. 7.↵
   1. Croxtall JD

   . Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1733–53.

   OpenUrlCrossRefPubMed
8. 8.
   1. Nograles KE,
   2. Davidovici B,
   3. Krueger JG

   . New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29:3–9.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Kurd SK,
   2. Troxel AB,
   3. Crits-Christoph P,
   4. Gelfand JM

   . The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010;146:891–5.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Brauchli YB,
    2. Jick SS,
    3. Miret M,
    4. Meier CR

    . Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 2009;129:2604–12.

    OpenUrlPubMed
11. 11.
    1. Gelfand JM,
    2. Neimann AL,
    3. Shin DB,
    4. Wang X,
    5. Margolis DJ,
    6. Troxel AB

    . Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735–41.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Broadley SA,
    2. Deans J,
    3. Sawcer SJ,
    4. Clayton D,
    5. Compston DA

    . Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000;123(Pt 6):1102–11.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Gelfand JM,
    2. Berlin J,
    3. Van Voorhees A,
    4. Margolis DJ

    . Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425–9.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Gniadecki R,
    2. Robertson D,
    3. Molta CT,
    4. et al

    . Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J Eur Acad Dermatol Venereol 2012;26:1436–43.

    OpenUrlPubMed
15. 15.↵
    1. Lebwohl MG,
    2. Tan MH,
    3. Meador SL,
    4. Singer G

    . Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001;44:77–82.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.
    1. Meier M,
    2. Sheth PB

    . Clinical spectrum and severity of psoriasis. Curr Probl Dermatol 2009;38:1–20.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Baran R

    . The burden of nail psoriasis: an introduction. Dermatology 2010;221(Suppl 1):1–5.

    OpenUrlPubMed
18. 18.↵
    1. Paul C,
    2. Gallini A,
    3. Maza A,
    4. et al

    . Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):2–11.

    OpenUrl
19. 19.↵
    1. James W,
    2. Berger T,
    3. Elston D

    . Andrews' diseases of the skin: clinical dermatology. 10th ed. New York: Saunders; 2005.
20. 20.
    1. Rosenbach M,
    2. Hsu S,
    3. Korman NJ,
    4. et al

    . Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62:655–62.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Long CC,
    2. Finlay AY,
    3. Averill RW

    . The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992;128:1129–30.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Nagel T,
    2. Schunk J

    . Using the hand the estimate the surface area of a burn in children. Pediatr Emerg Care 1997;13:254–5.

    OpenUrlPubMed
23. 23.↵
    E45 cream (light liquid paraffin, white soft paraffin, lanolin); last updated January 25, 2011. Available from: http://www.netdoctor.co.uk/medicines/100000887.html. Accessed December 20, 2011.
24. 24.↵
    1. Lebwohl M,
    2. Quijije J,
    3. Gilliard J,
    4. Rollin T,
    5. Watts O

    . Topical calcitriol is degraded by ultraviolet light. J Invest Dermatol 2003;121:594–5.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Murphy G,
    2. Reich K

    . In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol 2011;25(Suppl 4):3–8.

    OpenUrlPubMed
26. 26.↵
    1. Jacobi A,
    2. Braeutigam M,
    3. Mahler V,
    4. Schultz E,
    5. Hertl M

    . Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology 2008;216:133–6.

    OpenUrlPubMed
27. 27.↵
    1. Brune A,
    2. Miller DW,
    3. Lin P,
    4. Cotrim-Russi D,
    5. Paller AS

    . Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007;24:76–80.

    OpenUrlPubMed
28. 28.↵
    1. Thaçi D,
    2. Salgo R

    . The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatovenerol Alp Panonica Adriat 2007;16:58, 60–2.

    OpenUrlPubMed
29. 29.↵
    1. Halevy S,
    2. Sukenik S

    . Different modalities of spa therapy for skin diseases at the Dead Sea area. Arch Dermatol 1998;134:1416–20.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Lapolla W,
    2. Yentzer BA,
    3. Bagel J,
    4. Halvorson CR,
    5. Feldman SR

    . A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011;64:936–49.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Yones SS,
    2. Palmer RA,
    3. Garibaldinos TT,
    4. Hawk JL

    . Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006;142:836–42.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Markham T,
    2. Rogers S,
    3. Collins P

    . Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. Arch Dermatol 2003;139:325–8.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Herrier RN

    . Advances in the treatment of moderate-to-severe plaque psoriasis. Am J Health Syst Pharm 2011;68:795–806.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. de Berker D

    . Management of psoriatic nail disease. Semin Cutan Med Surg 2009;28:39–43.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Sticherling M,
    2. Augustin M,
    3. Boehncke WH,
    4. et al

    . Therapy of psoriasis in childhood and adolescence–a German expert consensus. J Dtsch Dermatol Ges 2011;9:815–23.

    OpenUrlPubMed
36. 36.↵
    Enbrel [homepage]. Thousand Oaks, CA: Immunex Corporation; 2011. Available from: http://www.enbrel.com/HCP/home.jspx. Accessed December 10, 2011.
37. 37.
    1. Papp KA,
    2. Tyring S,
    3. Lahfa M,
    4. et al

    . A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12.

    OpenUrlCrossRefPubMedWeb of Science
38. 38.
    1. Turner D,
    2. Picot J,
    3. Cooper K,
    4. Loveman E

    . Adalimumab for the treatment of psoriasis. Health Technol Assess 2009;13(Suppl 2):49–54.

    OpenUrl
39. 39.
    1. Mrowietz U,
    2. Kragballe K,
    3. Reich K,
    4. et al

    . An assessment of adalimumab efficacy in three phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol 2013;168:374–80.

    OpenUrlPubMed
40. 40.
    1. Menter A,
    2. Reich K,
    3. Li S,
    4. Guzzo C

    . Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical trials. J Am Acad Dermatol 2008;58(Suppl 2):AB120.

    OpenUrl
41. 41.↵
    1. Wolverton SE

    1. Callen JP,
    2. Kulp-Shorten CL

    . Methotrexate. In: Wolverton SE, ed. Comprehensive dermatologic drug therapy. 3rd ed. Indianapolis: Sauders; 2013: 169–81.
42. 42.
    1. O'Quinn RP,
    2. Miller JL

    . The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002;138:644–8.

    OpenUrlCrossRefPubMedWeb of Science
43. 43.
    1. Oh CJ,
    2. Das KM,
    3. Gottlieb AB

    . Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42:829–30.

    OpenUrlCrossRefPubMedWeb of Science
44. 44.
    1. Gottlieb AB,
    2. Evans R,
    3. Li S,
    4. et al

    . Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534–42.

    OpenUrlCrossRefPubMedWeb of Science
45. 45.
    1. Bartelds GM,
    2. Wijbrandts CA,
    3. Nurmohamed MT,
    4. et al

    . Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817–21.

    OpenUrlAbstract/FREE Full Text
46. 46.
    1. Leonardi CL,
    2. Kimball AB,
    3. Papp KA,
    4. et al

    . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665–74.

    OpenUrlCrossRefPubMedWeb of Science
47. 47.
    1. Papp KA,
    2. Langley RG,
    3. Lebwohl M,
    4. et al

    . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675–84.

    OpenUrlCrossRefPubMedWeb of Science
48. 48.
    1. Dogra S,
    2. Jain A,
    3. Kanwar AJ

    . Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereol 2012 July 23. [Epub ahead of print].
49. 49.↵
    1. Kalb RE,
    2. Strober B,
    3. Weinstein G,
    4. Lebwohl M

    . Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824–37.

    OpenUrlCrossRefPubMedWeb of Science
50. 50.↵
    1. Wolverton SE

    1. Callen JP,
    2. Kulp-Shorten CL,
    3. Wolverton SE

    . Methotrexate. In: Wolverton SE, ed. Comprehensive dermatologic drug therapy. 1st ed. Philadelphia: W.B. Saunders; 2001. p. 147–64.
51. 51.
    1. Dogra S,
    2. Krishna V,
    3. Kanwar AJ

    . Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study. Clin Exp Dermatol 2012;37:729–34.

    OpenUrlPubMed
52. 52.↵
    1. Rosmarin DM,
    2. Lebwohl M,
    3. Elewski BE,
    4. Gottlieb AB

    . Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010;62:838–53.

    OpenUrlPubMed
53. 53.↵
    1. Wolverton SE

    1. Koo JYM,
    2. Lee CS,
    3. Maloney JE

    . Cyclosporine and related drugs. In: Wolverton SE, ed. Comprehensive dermatological drug therapy. 1st ed. Philadelphia: WB Saunders; 2001. p. 205–29.
54. 54.
    1. Maza A,
    2. Montaudie H,
    3. Sbidian E,
    4. et al

    . Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol 2011;25(Suppl 2):19–27.

    OpenUrlPubMed
55. 55.↵
    Humira [homepage]. Princeton, NJ: Abbott Laboratories; 2011. Available from: http://www.humira.com/default.aspx?cid=ppc_ppd_hum_ggl_brand_3018. Accessed November 4, 2011.
56. 56.
    British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800–5.

    OpenUrlAbstract/FREE Full Text
57. 57.↵
    1. Schiff MH,
    2. Burmester GR,
    3. Kent JD,
    4. et al

    . Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889–94.

    OpenUrlAbstract/FREE Full Text
58. 58.↵
    1. Fallahi-Sichani M,
    2. Flynn JL,
    3. Linderman JJ,
    4. Kirschner DE

    . Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability. J Immunol 2012;188:3169–78.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    1. Lebwohl M,
    2. Bagel J,
    3. Gelfand JM,
    4. et al

    . From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94–105.

    OpenUrlCrossRefPubMedWeb of Science
60. 60.↵
    Centers for Disease Control and Prevention. Recommended adult immunization schedule—United States, 2011. MMWR Morb Mortal Wkly Rep 2011;60:1–4.

    OpenUrlPubMed
61. 61.↵
    1. Dommasch E,
    2. Gelfand JM

    . Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 2009;22:418–30.

    OpenUrlCrossRefPubMedWeb of Science
62. 62.↵
    1. Mitra A,
    2. Fallen RS,
    3. Lima HC

    . Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2013;44:173–82.

    OpenUrlPubMed
63. 63.↵
    1. Ryan C,
    2. Leonardi CL,
    3. Krueger JG,
    4. et al

    . Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306:864–71.

    OpenUrlCrossRefPubMedWeb of Science
64. 64.↵
    1. Reddy M,
    2. Torres G,
    3. McCormick T,
    4. et al

    . Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010;37:413–25.

    OpenUrlCrossRefPubMedWeb of Science
65. 65.↵
    1. Dreiher J,
    2. Kresch FS,
    3. Comaneshter D,
    4. Cohen AD

    . Risk of Herpes zoster in patients with psoriasis treated with biologic drugs. J Eur Acad Dermatol Venereol 2012;26:1127–32.

    OpenUrlPubMed
66. 66.↵
    1. Zhang J,
    2. Xie F,
    3. Delzell E,
    4. et al

    . Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43–9.

    OpenUrlPubMedWeb of Science
67. 67.↵
    1. Marehbian J,
    2. Arrighi HM,
    3. Hass S,
    4. Tian H,
    5. Sandborn WJ

    . Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009;104:2524–33.

    OpenUrlCrossRefPubMedWeb of Science
68. 68.↵
    1. Izumi A

    . Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal? Hawaii Med J 2009;68:277–8.

    OpenUrlPubMed
69. 69.↵
    1. Russman AN,
    2. Lederman RJ,
    3. Calabrese LH,
    4. Embi PJ,
    5. Forghani B,
    6. Gilden DH

    . Multifocal varicella-zoster virus vasculopathy without rash. Arch Neurol 2003;60:1607–9.

    OpenUrlCrossRefPubMedWeb of Science
70. 70.↵
    1. Brunton L,
    2. Lazo J,
    3. Parker K

    . Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill Professional; 2006.
71. 71.↵
    BlueCross BlueShield of Alabama. TNF antagonists and other biologics. Medical policy no. 061. Available from: www.bcbsal.com/providers/policies/final/061.pdf. Accessed March 26, 2012.
72. 72.↵
    1. Lam J,
    2. Polifka JE,
    3. Dohil MA

    . Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59:295–315.

    OpenUrlCrossRefPubMed
73. 73.↵
    1. Wolverton SE

    1. Nguyen EQ,
    2. Wolverton SE

    . Systemic retinoids. In: Wolverton SE, ed. Comprehensive dermatological drug therapy. 1st ed. Philadelphia: WB Saunders; 2001. p. 269–310.
74. 74.↵
    1. Roenigk HH Jr.,
    2. Auerbach R,
    3. Maibach H,
    4. Weinstein G,
    5. Lebwohl M

    . Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478–85.

    OpenUrlCrossRefPubMedWeb of Science
75. 75.↵
    1. Bray AP,
    2. Barnova I,
    3. Przemioslo R,
    4. Kennedy CT

    . Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy. Br J Dermatol 2012;166:1125–7.

    OpenUrlPubMed
76. 76.↵
    1. Saurat JH,
    2. Guerin A,
    3. Yu AP,
    4. et al

    . High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010;220:128–37.

    OpenUrlCrossRefPubMed
77. 77.↵
    1. Ponticelli C,
    2. Cucchiari D,
    3. Graziani G

    . Hypertension in kidney transplant recipients. Transpl Int 2011;24:523–33.

    OpenUrlPubMed